Investing.com - Financial Markets Worldwide
Open in App

CSPC Pharmaceutical Group Ltd (1093)

Hong Kong
Symbol
Exchange
Currency
1093·Hong Kong·HKD
CHJTF·OTC Markets·USD
1093·Frankfurt·EUR
1093·TradeGate·EUR
Currency in HKD
8.69
-0.16(-1.81%)
Closed·

1093 Financial Summary

Key Ratios

P/E Ratio26.29
Price/Book2.1
Debt / Equity1.86%
Return on Equity9.57%
Dividend Yield3.28%
EBITDA5.11B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa27,866.8730,936.931,450.1129,009.2526,005.98
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa21,135.0922,256.4122,176.6920,298.7117,058.5
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa6,249.266,759.637,016.015,366.153,961.03
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa5,605.196,091.395,873.334,328.043,882.11
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa34,741.5841,769.7746,282.1744,388.9946,697.91
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa7,226.048,95810,182.579,634.0310,177.87
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa26,828.2331,641.8835,018.0133,866.2934,550.12
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa1,721.333,825.91,163.632,130.492,926.46
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa4,636.637,627.064,178.824,534.665,831.64
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-637.33-6,795.98865.86-3,858.2-3,878.04
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-2,196.61-1,904.07-2,559.58-5,253.33-2,611.67
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa1,800.25-1,058.862,489.99-4,573.47-662.88
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.29%
Dividend Yield
3.28%
Industry Median 2.71%
Annualized payout
0.29
Paid annually
5-Years Growth
+19.41%
Growth Streak
Unlock

Analyst Ratings

18 Buy
2 Hold
3 Sell
Ratings:
23 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.72
(+34.85% Upside)

Earnings

Latest Release
May 27, 2026
EPS / Forecast
0.08 / 0.10
Revenue / Forecast
6.47B / 7.52B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were CSPC Pharma's earnings for the latest quarter?

The CSPC Pharma EPS (TTM) is 0.29. CSPC Pharma reported sales of 6,465.33, net income of 859.79, and EPS of 0.08 for the latest quarter.

What was CSPC Pharma's net income for the latest quarter?

CSPC Pharma's net income for the latest quarter was 859.79.

How did CSPC Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 6,114.91 million CNY in the previous quarter to 6,465.33 million CNY in the latest quarter, and net income moved from 370.72 million CNY to 859.79 million CNY compared to the previous quarter.

What is CSPC Pharma's net profit margin on a TTM basis?

CSPC Pharma's trailing twelve months (TTM) net profit margin is 12.82%.

How does CSPC Pharma's debt to equity ratio compare to industry standards?

CSPC Pharma's total debt-to-equity ratio is 1.86%.

What is CSPC Pharma's return on investment on a TTM basis?

CSPC Pharma's trailing twelve months (TTM) return on investment (ROI) is 9.57%.

How has CSPC Pharma's total revenue grown this year?

CSPC Pharma's total revenue was 6,114.91 million CNY in the previous quarter and 6,465.33 million CNY in the latest quarter.

What is CSPC Pharma's gross margin on a TTM basis?

CSPC Pharma's trailing twelve months (TTM) gross margin is 65.29%%.

What was CSPC Pharma's revenue per share for the latest quarter?

CSPC Pharma's revenue per share for the latest quarter was 5.82.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.